ADAM17 and cancer: Our study identifies ADAM17 as a key cooperating factor and druggable target in oncogenic KRAS‐driven LAC and thus provides the rationale to employ ADAM17‐based therapeutic strategies for targeting oncogenic KRAS‐addicted cancers.